Zoetis Inc. (NYSE:ZTS) Shares Purchased by Pinnacle Financial Partners Inc

Pinnacle Financial Partners Inc raised its position in Zoetis Inc. (NYSE:ZTS) by 0.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 46,136 shares of the company’s stock after buying an additional 271 shares during the period. Pinnacle Financial Partners Inc’s holdings in Zoetis were worth $7,520,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Pensionfund Sabic boosted its holdings in Zoetis by 55.6% in the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock worth $1,825,000 after buying an additional 4,000 shares during the last quarter. Callahan Advisors LLC boosted its holdings in Zoetis by 90.4% in the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock worth $2,135,000 after buying an additional 6,221 shares during the last quarter. PFW Advisors LLC acquired a new stake in Zoetis in the 4th quarter worth about $1,764,000. CIBC Asset Management Inc boosted its holdings in Zoetis by 24.1% in the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock worth $38,617,000 after buying an additional 46,050 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in Zoetis by 10.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock worth $569,834,000 after buying an additional 279,092 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently issued reports on ZTS. Morgan Stanley lowered their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Leerink Partners started coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. Barclays boosted their target price on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Finally, Stifel Nicolaus lowered their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $215.40.

Zoetis Stock Up 1.9 %

ZTS stock opened at $160.39 on Friday. The firm has a market cap of $71.82 billion, a PE ratio of 29.32, a PEG ratio of 2.78 and a beta of 0.90. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The firm’s 50 day moving average price is $166.51 and its 200-day moving average price is $177.99. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, equities research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.25%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is 36.56%.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by corporate insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.